HAE logo

HAE

Haemonetics CorporationNYSEHealthcare
$56.83+1.05%ClosedMarket Cap: $2.66B

As of 2026-04-06

Valuation

View Details

P/E (TTM)

15.16

PEG

0.43

P/B

2.92

P/S

2.02

EV/EBITDA

9.38

DCF Value

$686.33

FCF Yield

11.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

58.5%

Operating Margin

19.2%

Net Margin

13.3%

ROE

20.3%

ROA

12.0%

ROIC

8.7%

Financials

View All
PeriodRevenueNet IncomeEPS
Q3 2026$339.0M$44.7M$0.95
Q2 2026$327.3M$38.7M$0.81
Q1 2026$321.4M$34.0M$0.70
Q4 2025$330.6M$58.0M$1.17

Analyst Ratings

View All
CitigroupNeutral
2026-03-11
MizuhoOutperform
2026-02-06
CitigroupNeutral
2026-02-06
BTIGBuy
2026-02-06
Barrington ResearchOutperform
2026-02-06

Trading Activity

Insider Trades

View All
KROLL MARK Wdirector
BuyWed Nov 12
Galvin Royofficer: EVP, Chief Commercial Officer
SellMon Nov 03
Miller Laurie A.officer: SVP, Human Resources
SellWed Sep 24
Zane Ellen Mdirector
SellFri Jul 25
Pomeroy Clairedirector
SellFri Jul 25

Company Info

Sector

Healthcare

Industry

Country

US

Exchange

NYSE

Beta

0.36

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Peers